Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 1/20 | 0.57 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.55 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.53 |
| ▸ | KIT | P10721 | 2/20 | 0.52 |
| ▸ | RET | P07949 | 2/20 | 0.52 |
| ▸ | KDR | P35968 | 2/20 | 0.52 |
| ▸ | LCK | P06239 | 2/20 | 0.51 |
| ▸ | EGFR | P00533 | 5/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | GAK | O14976 | 1/20 | 0.50 |
| ▸ | SRC | P12931 | 1/20 | 0.50 |
| ▸ | PI4KA | P42356 | 1/20 | 0.50 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.50 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.50 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30103402 | 1.00 | PDE5A (0.57) | PDE5AMAP4K4ENPP1KITRET | |
| SCHEMBL15127844 | 0.90 | ENPP1 (0.68) | PDE5AMAP4K4ENPP1KITRET | |
| SCHEMBL29761271 | 0.89 | MAP4K4 (0.52) | PDE5AMAP4K4ENPP1KITRET | |
| SCHEMBL160593 | 0.89 | MAP4K4 (0.52) | PDE5AMAP4K4ENPP1KITRET | |
| SCHEMBL24355412 | 0.87 | GAK (0.56) | ENPP1KDREGFRGAK | |
| SCHEMBL8230611 | 0.86 | EGFR (0.51) | PDE5AMAP4K4RETKDRLCK | |
| SCHEMBL4417590 | 0.86 | PDE5A (0.51) | PDE5AMAP4K4RETKDRLCK | |
| SCHEMBL17661304 | 0.86 | PDE5A (0.51) | PDE5AMAP4K4KITRETKDR | |
| SCHEMBL30968992 | 0.86 | EGFR (0.51) | PDE5AMAP4K4RETKDRLCK | |
| SCHEMBL4424669 | 0.84 | KDR (0.56) | MAP4K4ENPP1KITRETKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111065635-B | Novel pyrimidine derivatives as MTH1 inhibitors | 无锡安万生物科技有限公司 | 2022-07-22 | — | — | CN | claimed |
| CN-113149969-A | Andrographolide derivative with antitumor activity and preparation method thereof | 籍建亚 | 2021-07-23 | — | — | CN | claimed |
| CN-111087351-A | Synthetic method of erlotinib intermediate | 山东罗欣药业集团股份有限公司 | 2020-05-01 | — | — | CN | claimed |
| CN-104725364-B | The amine derivative of 6,7 dimethoxyquinazoline 4, its preparation method and medical usage | 江苏省中国科学院植物研究所 | 2017-09-15 | — | — | CN | claimed |
| EP-0892790-A1 | NEW QUINAZOLINE-4-AMINO-2-(PIPERIDINE-1-YL-4-SUBSTITUTED) DERIVATIVES HAVING ANTI-HYPERTENSIVE ACTIVITY, A METHOD FOR THEIR PREPARATION AND THEIR PHARMACEUTICAL USE | ROTTA RESEARCH LABORATORIUM S.P.A. (IT) | 1999-01-27 | — | — | EP | claimed |
| WO-1997037979-A1 | NEW QUINAZOLINE-4-AMINO-2-(PIPERIDINE-1-YL-4-SUBSTITUTED) DERIVATIVES HAVING ANTI-HYPERTENSIVE ACTIVITY, A METHOD FOR THEIR PREPARATION AND THEIR PHARMACEUTICAL USE | ROTTA RESEARCH LABORATORIUM S.P.A. (IT) | 1997-10-16 | — | — | WO | claimed |
| EP-0225866-B1 | QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE | Gerot-Pharmazeutika Gesellschaft m.b.H. (AT) | 1991-09-25 | — | — | EP | claimed |
| EP-0004389-B1 | 4-AMINO-6,7-DIMETHOXY QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION, THEIR USE AND A PHARMACEUTICAL COMPOSITION | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1982-04-07 | — | — | EP | claimed |
| EP-0039190-A1 | 2-(1-Piperazinyl)-4-pyrimidinamines and related compounds | AMERICAN HOME PRODUCTS CORPORATION (US) | 1981-11-04 | — | — | EP | claimed |
| EP-0004389-A2 | 4-Amino-6,7-dimethoxy quinazoline derivatives, process for their preparation, their use and a pharmaceutical composition | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1979-10-03 | — | — | EP | claimed |
| WO-2024194756-A1 | MODULATING THE INNATE IMMUNITY OF RNA | PFIZER INC. (US) | 2024-09-26 | — | — | WO | disclosed |
| CN-118141921-A | Use of CAMK2 inhibitors for the preparation of a medicament for reducing resistance to EGFR-driven cancers | 四川大学 | 2024-06-07 | — | — | CN | disclosed |
| EP-4248975-A2 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | Rigel Pharmaceuticals, Inc. (US) | 2023-09-27 | — | — | EP | disclosed |
| US-20230293533-A1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | HOFFMANN-LA ROCHE INC. | 2023-09-21 | — | — | US | disclosed |
| US-11723908-B2 | Quinazoline derivatives as antitumor agents | SUZHOU ZANRONG PHARMA LIMITED (CN) | 2023-08-15 | — | — | US | disclosed |
| EP-0030156-A1 | Quinazoline derivatives, processes for their preparation and pharmaceutical compositions containing them | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1981-06-10 | — | — | EP | disclosed |
| EP-0004389-A2 | 4-Amino-6,7-dimethoxy quinazoline derivatives, process for their preparation, their use and a pharmaceutical composition | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1979-10-03 | — | — | EP | disclosed |
| EP-0004389-A2 | 4-Amino-6,7-dimethoxy quinazoline derivatives, process for their preparation, their use and a pharmaceutical composition | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1979-10-03 | — | — | EP | disclosed |
| EP-0004389-A2 | 4-Amino-6,7-dimethoxy quinazoline derivatives, process for their preparation, their use and a pharmaceutical composition | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1979-10-03 | — | — | EP | disclosed |
| US-3800039-A | ANTITHROMBOGENIC PROCESS EMPLOYING SUBSTITUTED 6,7-DIALKOXYQUINAZOLINES | MEAD JOHNSON & CO | 1974-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11723908-B2 | Quinazoline derivatives as antitumor agents | ABL1, TP53, JAK1 | PDE5A 3374/4885MAP4K4 72/4885ENPP1 2020/4885 |
| US-20230293533-A1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ABL1, TP53, JAK1 | PDE5A 3374/4885MAP4K4 72/4885ENPP1 2020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.